Smartphone-enabled continuous glucose monitoring system earns CE mark

The Guardian Connect CGM system--Courtesy
of Medtronic

Medtronic has earned a CE mark for the Guardian Connect mobile continuous glucose monitoring (CGM) system for individuals with diabetes who use insulin injection therapy. This is the first CE mark given to any smartphone-enabled CGM system.

Checking glucose levels on Guardian Connect is as simple as checking text messages or emails on a smartphone, Medtronic ($MDT) explained. Alerts can also be used to notify a patient of high or low glucose levels, determined by a preset measurement threshold.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

"Having continuous, real-time access to glucose values and being alerted to important trends and events is key for people with diabetes," said Annette Brüls, president of diabetes service and solutions at Medtronic.

Patients can take advantage of automatic uploads to CareLink therapy management software, so there is no need for bulk data upload by patients or healthcare providers. Brüls noted that the CareLink system “arms healthcare providers, their patients and care partners with actionable data to help improve day-to-day diabetes management and make long-term therapy adjustments."

The system uses a small wearable CGM device that takes glucose measurements every 5 minutes and sends readings to a smartphone app. Users can share data through the aforementioned CareLink system and can also set up SMS text messages to send to care providers.

The system is set to launch country-by-country in the second quarter of 2017 beginning in select countries in Europe, Asia Pacific and Latin America. The smartphone app will initially be available on iOS with an Android version currently in development.

- here's the release

Related Articles: 
Abbott snags CE mark for continuous glucose monitor with no finger sticks for kids
U.S. pivotal trial starts for Senseonics glucose monitor implant with data due in June
Medtronic, Qualcomm partner for disposable, connected Type 2 diabetes continuous glucose monitors

Read more on

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.